Salmonella Protein AvrA Activates the STAT3 Signaling Pathway in Colon Cancer. Read more about Salmonella Protein AvrA Activates the STAT3 Signaling Pathway in Colon Cancer.
MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Read more about MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Read more about Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.
Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling. Read more about Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Read more about Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Read more about JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Read more about A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer.
The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Read more about The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc.
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Read more about Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
